- 200 patients in Bolton recruited to major trial looking for new ways of treating critical illnesses
- GenOMICC uses the DNA of people with severe infections or injuries to improve understanding
- Study has already identified and confirmed an effective treatment against severe COVID-19
Bolton NHS Foundation Trust has recruited a milestone 200 patients in a major research trial looking to find new treatments for critical illnesses.
The GenOMICC trial is using the DNA of people with severe infections or injuries to understand what causes some people to be more sick.
Researchers hope this vital information will help develop better treatments for patients who have critical illnesses, such as sepsis, influenza and Group A Strep, in the future.
The global study is taking place across 13 countries with more than 41,000 patients recruited to date
Dr Gareth Hughes, Critical Care Consultant and Principal Investigator for the GenOMICC trial at Bolton NHS Foundation Trust, said
“The fantastic work of our research nurses and team has allowed us to actively contribute to the study, with Bolton being in the top 10-20 recruiting sites for a number of months over the course of the study.
“We had recently extended the study to include children with our neonatal intensive care. The ongoing work helps to ensure Bolton continues to contribute to key research which truly has worldwide relevance. As a trust we aim to grow our research portfolio over the coming years to ensure our patients receive excellent care and have the opportunity to benefit from clinical trials.”
A new treatment for critically ill patients with COVID-19, known as baricitinib, has already been discovered through the trial, making GenOMICC the only critical care or infectious disease genetics study to ever directly lead to a new effective drug.
To find out more about taking part in research in Bolton, visit Bolton NHS Foundation Trust’s website. More information about the GenOMICC study is on their website.
